Levin Capital Strategies, L.P. Bio N Tech Se Transaction History
Levin Capital Strategies, L.P.
- $1.03 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding BNTX
# of Institutions
357Shares Held
38.3MCall Options Held
2.45MPut Options Held
2.29M-
Baillie Gifford & CO8.31MShares$984 Million0.75% of portfolio
-
Primecap Management CO Pasadena, CA4.52MShares$535 Million0.4% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.36MShares$516 Million2.05% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$224 Million0.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U01.81MShares$214 Million0.88% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $28.7B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...